Epi-743 (DrugBank: -)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
21 | Mitochondrial disease | 1 |
156 | Rett syndrome | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01642056 (ClinicalTrials.gov) | September 1, 2012 | 14/7/2012 | EPI-743 for Metabolism or Mitochondrial Disorders | Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction | Mitochondrial Disease;Neurology;Myoptahy | Drug: EPI-743;Drug: Placebo | National Human Genome Research Institute (NHGRI) | NULL | Completed | 2 Years | 11 Years | All | 20 | Phase 1;Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2012-005021-76-IT (EUCTR) | 31/01/2013 | 11/12/2012 | Phase 2A clinical trial conducted on children affected by Rett syndrome and who are casually administered with the experimental treatment, EPI-743, compared versus the se of placebo. | A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome | Rett Syndrome MedDRA version: 14.1;Level: HLGT;Classification code 10021605;Term: Inborn errors of metabolism;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: EPI-743 Product Code: NA Other descriptive name: Alpha-tocotrienol quinone | EDISON PHARMACEUTICALS INC. | NULL | Not Recruiting | Female: yes Male: no | Phase 2A | Italy | |||
2 | NCT01822249 (ClinicalTrials.gov) | January 2013 | 25/3/2013 | Phase 2 Study of EPI-743 for Treatment of Rett Syndrome | A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome | Rett Syndrome | Drug: EPI-743;Drug: Placebo | Edison Pharmaceuticals Inc | NULL | Completed | N/A | 18 Years | Female | 24 | Phase 2 | Italy |